Skip to main content
Premium Trial:

Request an Annual Quote

Shopping for Space?

Despite closing some facilities, Merck is on the hunt for a new spot in the UK, according to FiercePharma. The UK's Business Weekly adds that "London property agents have been retained to find a base of between 80,000 and 100,000 sq ft, with Cambridge one of the prime locations under review." In the Pipeline's Derek Lowe, adds [link original]: "if only there were a large research campus that they could somehow get their hands on, convenient to both Cambridge and London, with all the facilities they might need … hmmm…"

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.